Maa: Euroopan unioni
Kieli: englanti
Lähde: EMA (European Medicines Agency)
glecaprevir, pibrentasvir
AbbVie Deutschland GmbH Co. KG
J05AP57
glecaprevir, pibrentasvir
Antivirals for systemic use
Hepatitis C, Chronic
Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.
Revision: 22
Authorised
2017-07-26
64 B. PACKAGE LEAFLET 65 PACKAGE LEAFLET: INFORMATION FOR THE USER MAVIRET 100 MG/40 MG FILM-COATED TABLETS glecaprevir/pibrentasvir READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Maviret is and what it is used for 2. What you need to know before you take Maviret 3. How to take Maviret 4. Possible side effects 5. How to store Maviret 6. Contents of the pack and other information 1. WHAT MAVIRET IS AND WHAT IT IS USED FOR Maviret is an antiviral medicine used to treat adults and children 3 years and older with long-term (‘chronic’) hepatitis C. This is an infectious disease that affects the liver, caused by the hepatitis C virus. Maviret contains the active substances glecaprevir and pibrentasvir. Maviret works by stopping the hepatitis C virus from multiplying and infecting new cells. This allows the infection to be eliminated from the body. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MAVIRET DO NOT TAKE MAVIRET IF: you are allergic to glecaprevir, pibrentasvir or any of the other ingredients of this medicine (listed in section 6). you have severe liver problems other than from hepatitis C. you are taking the following medicines: atazanavir (for HIV infection) atorvastatin or simvastatin (to lower blood cholesterol) carbamazepine, phenobarbital, phenytoin, primidone (normally used for epilepsy) dabigatran etexilate (to prevent blood clots) ethinyl oestradiol-containing medicines (such as contraception medicines, including vaginal rings, transdermal patch Lue koko asiakirja
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE MEDICINAL PRODUCT Maviret 100 mg/40 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 100 mg glecaprevir and 40 mg pibrentasvir. Excipient with known effect Each film-coated tablet contains 7.48 mg lactose (as monohydrate). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). Pink, oblong, biconvex, film-coated tablet of dimensions 18.8 mm x 10.0 mm, debossed on one side with ‘NXT’. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older (see sections 4.2, 4.4. and 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Maviret treatment should be initiated and monitored by a physician experienced in the management of patients with HCV infection. Posology _Adults, adolescents aged 12 years and older, or children weighing at least 45 kg_ The recommended dose of Maviret is 300 mg/120 mg (three 100 mg/40 mg tablets), taken orally, once daily at the same time with food (see section 5.2). The recommended Maviret treatment durations for HCV genotype 1, 2, 3, 4, 5, or 6 infected patients with compensated liver disease (with or without cirrhosis) are provided in Table 1 and Table 2. TABLE 1: RECOMMENDED MAVIRET TREATMENT DURATION FOR PATIENTS WITHOUT PRIOR HCV THERAPY GENOTYPE RECOMMENDED TREATMENT DURATION NO CIRRHOSIS CIRRHOSIS GT 1, 2, 3, 4, 5, 6 8 weeks 8 weeks 3 TABLE 2: RECOMMENDED MAVIRET TREATMENT DURATION FOR PATIENTS WHO FAILED PRIOR THERAPY WITH PEG-IFN + RIBAVIRIN +/- SOFOSBUVIR, OR SOFOSBUVIR + RIBAVIRIN GENOTYPE RECOMMENDED TREATMENT DURATION NO CIRRHOSIS CIRRHOSIS GT 1, 2, 4-6 8 weeks 12 weeks GT 3 16 weeks 16 weeks For patients who failed prior therapy with an NS3/4A- and/or an NS5A inhibitor, see section 4.4. _Missed dose_ In case a dose of Maviret is missed, the prescribed dose can be taken within 18 hours after the time it w Lue koko asiakirja